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Abstract 
Background: The August 2013 publication of a large historical cohort study in the New England Journal of Medicine has reignited 
interest in the potential teratogenic effects of fluconazole when used in pregnant females.  Fluconazole is an effective and commonly-
utilized antifungal medication.  Thus, maternal and fetal exposure to fluconazole is expected in the general population, and 
pharmacists are expected to counsel patients regarding any risks to their prescribed treatment.   
Methods: A literature review of all published literature indexed to PubMed (January 1966 to October 2013) and International 
Pharmaceutical Abstracts (January 1975 to October 2013) including fluconazole and teratogenic effects and published in the English 
language was conducted. 
Results: Fourteen publications were included for analysis including case reports (n=7), cross-sectional research (n=2), and historical 
cohort studies (n=5).  
Conclusion: There appears to be little to no fetal risk resulting from a single dose or short duration antifungal therapy with 
fluconazole.  However, prolonged high-dose fluconazole therapy has increased potential to confer teratogenic effects.  In those cases, 
the risks of such therapy should be weighed against potential benefits. 
 
 
Introduction 
Initially introduced to the market in January 1990, fluconazole 
(FLU) is extensively used, especially as a 150 mg single dose 
for treatment of vaginal candidiasis.  Guidelines published by 
the Infectious Diseases Society of America (IDSA) suggest FLU 
treatment for a wide variety of fungal infections.  In 
candidiasis and cryptococcal disease, FLU is often listed as a 
primary therapy option.  Fluconazole is efficacious for the 
treatment of a wide range of candidal infections including 
nonneutropenic candidemia, suspected candidiasis in urinary 
tract infections, and pulmonary cryptococcosis.2,3  
Fluconazole exhibits excellent cerebrospinal fluid 
penetration, with concentrations exceeding 70% of serum 
values in dosages from 50 to 400 mg/day.4  As a result, FLU 
also has a prominent place in the treatment of numerous 
types of fungal central nervous system infections such as 
meningitis, often as a step down therapy after initial 
treatment with amphotericin B (AmB).2,3  Guidelines for 
antifungal therapy for blastomycosis, coccidioidomycosis, and 
histoplasmosis also list FLU as a primary, adjunct, or 
secondary treatment option.5-7 
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Though FLU has been suspected of being a teratogen since as 
early as 1992, it is still frequently used during pregnancy.  
Depression of the T-cell mediated immune response, high 
estrogen levels, reduced vaginal pH, and increased vaginal 
glycogen concentrations place pregnant women at an 
increased risk of vaginal candidiasis, which is easily treated 
with FLU.8,9  Additionally, the risk of dissemination of disease 
and mortality from coccidioidomycosis and coccidioidal 
meningitis is significantly higher in pregnant women.10  
Despite its popularity, FLU is thought to cross the placenta 
and achieve detectable or even therapeutic concentrations in 
amniotic fluid as well as fetal tissue and cord blood.  This 
property of FLU led to the preference of AmB deoxycholate or 
lipid formulations of AmB by most published guidelines for 
susceptible fungal infections in pregnancy.  The guideline 
preference for AmB is specifically directed toward pregnant 
females in the first trimester, which is the most critical period 
for development of embryonic and fetal malformations.9 
 
In August 2011, the U.S. Food and Drug Administration (FDA) 
issued a safety announcement concerning the use of FLU in 
pregnancy.  On the basis of several published case reports in 
humans11-14, and animals showing similar causative effects15, 
the FDA changed the pregnancy category of FLU from 
category C to category D for all indications except FLU 150 mg 
as a single dose for treatment of vaginal candidiasis, citing 
trends of “a rare and distinct set of birth defects in infants 
whose mothers were treated with the drug during the first 
trimester of pregnancy”.16 The FDA noted that these defects 
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included a short, broad head, abnormal looking face, 
abnormal development of the skullcap, oral cleft, bowing of 
the thigh bones, thin ribs and long bones, muscle weakness 
and joint deformities, and congenital heart disease.16   
 
Created in 1980, the FDA’s drug-associated pregnancy risk 
categories, which consist of the letter designations of A, B, C, 
D, or X, are assigned according to the known or potential fetal 
harm associated with drug therapy.  Category A represents 
the least proven harm, while category X represents definitive 
fetal harm that outweighs any benefit of use in pregnant 
women.  The change from category C to category D for most 
indications of FLU reflected what the FDA believed to be 
positive evidence of fetal risk in human studies, rather than 
evidence of risk from only animal studies.16 
 
In August 2013, the New England Journal of Medicine 
published a registry-based historical cohort study by 
Mølgaard-Nielsen et al. which assessed congenital 
malformations outcomes after exposure to FLU during the 
first trimester of pregnancy.17 The goal of this article is to 
conduct a comprehensive literature review that incorporates 
this most recent data with the other published literature 
regarding the safety of FLU in pregnancy, with the outcome 
of teratogenicity as a specific focus. 
 
Methods   
A comprehensive literature search was conducted to identify 
relevant literature regarding use of FLU during pregnancy and 
any potential association with congenital malformations.  The 
databases included in the search were PubMed (January 1966 
to October 2013) and International Pharmaceutical Abstracts 
(January 1975 to October 2013).  For PubMed, keywords, 
exploded terms, truncation, and controlled terminology were 
used.  The following search terms were used, both 
individually and in combination: “Fluconazole [Mesh]”, 
“pregnancy [Mesh]”, “congenital abnormalities [Mesh]”, 
“abnormalities, drug-induced [Mesh]”, “antifungal 
agents/adverse effects [Mesh]”, “pregnancy complications 
[Mesh]”, “pregnancy complications, infectious [Mesh]”, 
“teratogens [Mesh]”, “Fluconazole”, “abnormalities”, 
“pregnancy”, “birth”, “congenital”, “malformations”, and 
“teratogens”.  For International Pharmaceutical Abstracts, 
keyword searching and truncated derivations of the keywords 
were exclusively used.  Additional references were identified 
through a bibliographic search of included references.   
 
Studies were included for analysis if they were conducted in 
humans, examined an association between FLU use in 
pregnancy and congenital malformations as either a primary 
or secondary endpoint, and were available in English as a full-
text article.  Clinical trials, cohorts, case-controls, cross-
sectionals, case series, case reports, and letters to the editor 
were all considered for analysis.  In total, 14 references 
ultimately met the criteria for inclusion in this analysis. 
 
Results 
The association between FLU use during pregnancy and 
congenital malformations has been assessed in various types 
of published literature.  These studies are summarized in 
Table 1. 
 
Case Reports 
Eight individual cases were identified where FLU use during 
pregnancy was studied in relation to the development of 
congenital malformations.  The earliest of these was 
presented by Lee et al. in 199211, who reported the case of a 
premature infant born at 27-weeks to a 22-year-old mother 
who was treated for disseminated coccidioidomycosis with 
FLU 400 mg per day from before conception through delivery.  
The mother was in her second pregnancy, and she had a 
history of coccidioidal meningitis dating back to her first 
pregnancy.  After treatment with 2600 mg intravenous AmB 
and 131.5 mg intrathecal AmB, she was placed on FLU and 
remained on the medication through delivery due to late 
detection of her pregnancy at 23-weeks gestation.  Upon 
cesarean birth, the infant displayed multiple congenital 
malformations, including craniosynostosis, contractures of 
both upper and lower extremities, humeral-radial fusion, 
bowed tibia and femur, incomplete or shortened digits, and 
cleft palate.  These abnormalities produced a poor prognosis 
that led to withdrawal of life support and death of the infant.  
The authors were unable to differentiate their findings from 
Antley-Bixler syndrome, but suggested possible causation due 
to similar abnormalities in animal studies with FLU.11  
 
The same 22-year old mother described by Lee et al.11 had 
two subsequent pregnancies that were reported by Pursley et 
al.12 in 1996.  During her third pregnancy, the patient was 
nonadherent to therapy, delivered a healthy boy, and 
resumed FLU therapy.  She then remained on a regimen of 
FLU 400 mg/day for coccidioidal meningitis when she was yet 
again discovered to be 4-months pregnant (gravida 4), upon 
which FLU therapy was discontinued.  The female baby, born 
at full term, was found to have multiple craniofacial 
malformations (cleft palate, tracheomalacia, low ears, 
rudimentary epiglottis, and proptosis), multiple cardiac 
defects (ventricular septal defect and pulmonary artery 
hypoplasia), and multiple skeletal malformation (bowed 
femurs, clavicular fracture, thin and wavy ribs, absent distal 
phalanx, and arachnodactyly).  The infant died at 3 months of 
age from pneumonia, presumably secondary to 
tracheomalacia.12 
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Pursley et al.12 also reported the case of a 25-year old mother 
treated for coccidioidal meningitis with FLU 800 mg/day 
through delivery at 38 weeks gestation (with a FLU hiatus 
during weeks 7-9).  Congenital abnormalities found upon 
examination were as follows: flattened occiput, 
brachycephaly, trigonocephaly, supraorbital ridge hypoplasia, 
bitemporal narrowing, open cranial sutures, large anterior 
fontanel, maxillary hypoplasia, short ear helices, 
micrognathia, exotropia, bowed femurs, diffuse osteopenia, 
thin ribs, clavicles, and long bones, long metacarpals and 
phalanges, hypoplastic facial bones, craniofacial 
disproportion, slanted orbital roofs, tetralogy of Fallot, patent 
ductus arteriosus, right and left pulmonary artery hypoplasia, 
patent foramen ovale, and large ventricular septal defect.12 
 
In 1996, Wiesinger et al.18 described the case of a 24-year old 
female admitted at 16-weeks gestation with Candida sepsis.  
After failing an AmB test dose, the patient was placed on 
intravenous FLU therapy (400 mg/day), which was continued 
for 16 days, at which time she was converted to oral FLU 
therapy, which continued for an additional 34 days.  At        
39-weeks gestation the patient delivered a healthy female 
baby.18 
 
Aleck and Bartley13 reported another case of congenital 
malformation attributed to FLU exposure in 1997, describing 
a 27-year old mother treated with 400mg/day FLU for 
coccidioidal meningitis.  Due to clinical deterioration, the 
patient’s dose was increased to 800 mg/day.  Approximately 
4 weeks after the dose increase, the patient was determined 
to be pregnant, with an estimated gestation of 9 weeks; at 
that time FLU therapy was discontinued and AmB initiated.  
Due to further clinical deterioration, at approximately           
22-weeks gestation, FLU therapy was reinstituted (1200 
mg/day) and the AmB was discontinued.  At 31-weeks 
gestation, the patient delivered a male infant.  The baby was 
found to have multiple congenital malformations including 
soft calvarium, widely separated cranial sutures, prominent 
forehead, mild exorbitism, small hemangioma on the tip of 
the nose, posteriorly angulated ears with over folded helices, 
bilateral radiohumeral synostosis, and dysplastic hips.13 
 
Lopez-Rangel and Van Allen14 reported another case in 2005 
of a 9-month-old male infant born to a mother treated for 
vaginal candidiasis with FLU 800 mg per day from before 
conception to the 5th month of gestation and again from the 
6th month of gestation to delivery.  Upon birth, multiple 
congenital malformations were present.  Many of these 
abnormalities were consistent with those identified in other 
cases, such as craniosynostosis, proptosis and other 
recognizable dysmorphic facial features, contractures, and 
joint synostosis.  Other malformations included multiple 
symphalangism, mild to moderately diffuse cerebral 
dysfunction, moderate bilateral hearing loss, and short first 
toe. In this infant, a cardiac examination returned normal 
results.  The mother was a 30-year-old Aboriginal diagnosed 
with human immunodeficiency virus (HIV) infection leading to 
multiple medication exposures, including efavirenz, 
nevirapine, methadone, dapsone, pentamidine, and 
trimethoprim-sulfamethoxazole.  The infant’s neonatal period 
was also complicated by mild seizures due to neonatal 
abstinence syndrome, Streptococcus pneumonia, and 
bacteremia.14   
 
Two additional cases reported briefly in letters to the editor 
yielded mixed findings with exposure to FLU during 
pregnancy.  Sanchez and Moya19 confirmed multiple 
congenital malformations upon 32-week ultrasonography and 
post-birth echocardiography of an infant who died 7 days 
post-birth after being born to a 38-year-old-primigravida 
exposed to a single dose of FLU 150 mg near conception.  In 
contrast, Krcmery et al.20 failed to observe any abnormalities 
in an 18-month follow-up exam of a child born to a 24-year-
old pregnant woman at 41-weeks gestation after exposure to 
FLU 600 mg per day for 21 days starting in the 14th week of 
pregnancy.  The mother was switched to FLU for Torulopsis 
glabrata fungemia after developing intolerance to AmB on 
the first day of therapy.    
 
Cross-Sectional Studies 
Inman et al.21 conducted a survey of prescribers of FLU.  Of 
the 14,421 surveys returned, there were 289 pregnancies 
reported.  These reported pregnancies were divided into 
three groups: Group 1 received a single 150 mg dose of FLU 
(n=275), Group 2 received multiple (undefined number) 50 
mg doses (n=3) and Group 3 received multiple (undefined 
number) 150 mg doses (n=11).  There were five cases of fetal 
abnormality, all of which were from Group 1.  The authors 
were able to determine the approximate time of exposure to 
FLU relative to last menstrual period (LMP) for this sample 
and reported each case of malformation as follows: bilateral 
nephrosis with FLU exposure 12-weeks pre-LMP, hooded 
prepuce and minimal hypospadias with FLU exposure 15 
weeks pre-LMP, proximal hypospadias and bifid scrotum with 
FLU exposure 8 weeks pre-LMP, minor finger webbing and 3 
short fingers on the other hand with FLU exposure 1 week 
pre-LMP, and still birth along with Edwards Syndrome (i.e. 
Trisomy 18 and cardiac abnormalities) with FLU exposure     
26-weeks pre-LMP.21 
 
Campomori and Bonati22 briefly reported in a letter to the 
editor regarding 16 pregnant women who had contacted a 
drug information center concerned about possible 
teratogenic effects of FLU.  The estimated mean FLU 
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exposure was 291 mg (median 300 mg, range 150-1000), 
beginning at 4 ± 6 weeks gestation (range 1-26 weeks), with a 
duration of therapy of 1 ± 0.3 weeks.  Fifteen of the 
pregnancies resulted in normal, unremarkable births; one 
pregnancy involving twins ended in stillbirth, however no 
malformations were reported.22 
 
Cohort Studies 
Five cohort studies were identified that investigated the 
association of FLU with various birth defects.  The first of 
these was conducted in 1996 by Mastriacovo et al.23, who 
designed a prospective cohort study of women who 
contacted one of three Teratology Information Services 
centers in Italy during pregnancy.  The exposure group 
consisted of 226 women who had been exposed to FLU 
during the first trimester.  The control group consisted of 452 
women who had not been exposed to FLU during pregnancy.  
Of the parameters examined (i.e., induced abortions, 
miscarriages, stillbirths, congenital anomalies, prematurity, 
low birth weight, cesarean section, and long hospital stay), 
FLU exposure during the first trimester was only significantly 
associated with induced abortions [OR = 5.06 (95% CI, 2.28-
11.21)].  Odds ratios for nonsignificant variables were as 
follows: miscarriages [OR = 1.21, (95% CI, 0.67-2.21)], 
stillbirths [OR = 0.36 (95% CI, 0.03-3.90)], congenital 
anomalies [OR = 1.07 (95% CI, 0.41-2.77)], prematurity [OR = 
1.73 (95% CI, 0.60-4.97)], low birth weight [OR = 0.92 (95% CI, 
0.38-2.19)], cesarean section [OR = 0.91 (95% CI, 0.60-1.40)], 
and long hospital stay [OR = 0.87 (95% CI, 0.57-1.29)].23 
 
In 1999, Jick24 used the United Kingdom’s General Practice 
Research Database to identify 234 women who had been 
exposed to FLU during the first trimester of pregnancy.  Of 
those exposures, 92% received a single 150 mg dose of FLU, 
and the study group was matched by age and general 
practice with 1,629 women without exposure to FLU or other 
azole medications during pregnancy.  The study found no 
significant increased risk of malformations for FLU users 
compared with nonusers, with polydactyly-syndactyly, heart 
defects, and spina bifida among the abnormalities present.24    
 
Sørensen et al.25 identified 121 Danish women who had taken 
FLU during the first trimester of their pregnancies and had 
subsequently given birth to either a live or stillborn infant.  All 
pregnancies in North Jutland County from January 1, 1991, to 
December 31, 1996, were included in the study, a sample 
representative of 9 percent of the Danish national population 
during that time.  These pregnancies were identified using 
the Danish Medical Birth Registry (DMBR), which tracks all 
live and still births in Denmark since January 1, 1973, and 
stores data collected by midwives and doctors attending 
deliveries.  The DMBR follows infants up until one year of age, 
so it may be used along with the Danish National Registry of 
Patients (DNRP) to ascertain birth defect data.25   
 
Sørensen et al.25 identified FLU exposure during the first 
trimester using computerized prescription databases. Though 
the authors were unable to determine daily medication 
regimens or cumulative doses of FLU received, they assumed 
that most subjects were given a single 150 mg FLU tablet 
based on patterns and standards of vaginal candidiasis 
treatment in Denmark at the time.  The study found no 
significant association between FLU use and congenital 
malformations, both in the crude RR [0.62 (95% CI, 0.23-
1.68)] and in a RR adjusted for maternal age, birth order, 
gestational age, and maternal smoking status [0.65 ( 95% CI, 
0.24-1.77)].  Additionally, FLU use was found to have a 
nonsignificant association with low birth weight [RR = 1.17 
(95% CI 0.37-3.70)] and with preterm delivery [RR = 1.13 (95% 
CI, 0.61-2.09)].  None of the malformations were duplicative, 
with congenital hip dislocation, lacrimal stenosis, partial 
syndactyly, and ventricular septum deficiencies each 
appearing in one infant.  However, the study was not 
powered to detect more than a 1.8-fold increased risk of 
malformations, and the study design did not include 
spontaneous abortions or abortions performed due to 
prenatal diagnoses of malformation.25  
 
Nørgaard et al.26 published a 2008 study that expanded on 
the work of Sørensen et al.25, using the DMBR to identify 
women from four Danish counties who gave birth to either 
live or stillborn infants after the 20th week of gestation.  The 
study encompassed 31 percent of the country’s population, 
and depending on the county, set a date range from either 
1991, 1996, or 1998, through 2005.  Fluconazole exposure 
during the first trimester was identified using computerized 
prescription databases, and all women in the study group 
(N=1,079) received a “short-course,” or 1 to 4 days, of FLU 
therapy with cumulative exposures of either 150mg (74%), 
300mg (22%), 350mg (2%), or 600mg (2%).  Exclusions listed 
in the study were congenital hip dislocation, undescended 
testes, and known chromosomal aberrations such as Down’s 
syndrome.  The crude prevalence odds ratio (POR) for the 
study group compared to pregnancies not exposed to FLU 
(N=170,453) was found to be nonsignificant [1.1 (95% CI, 0.8-
1.5)], as was a POR adjusted for maternal smoking status, 
parity, maternal age, and prescriptions for antiepileptics and 
maternal diabetes [1.0 (95% CI, 0.8-1.4)].  No significant 
associations or definitive trends were found when congenital 
abnormalities were analyzed individually, though some 
malformations occurred multiple times within the study 
group, including cardiovascular, craniofacial, and 
musculoskeletal abnormalities, along with club foot and 
neural tube defects.26 
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In 2013 Mølgaard-Nielsen et al.17 conducted a registry-based 
historical cohort study of all live births in Denmark for the 
period January 1, 1996 through March 31, 2011 using the 
DMBR to assess for congenital malformation outcomes after 
exposure to FLU during the first trimester of pregnancy.  
Fluconazole exposure during the first trimester was identified 
using computerized prescription databases, resulting in a FLU 
exposure group of 7,352 cases.  For the non-exposure group, 
there were 968,236 cases.  The primary endpoint was major 
birth defect; a composite endpoint comprising 15 birth 
defects thought to be associated with azole antifungals.  
Additionally, exposure to FLU was assessed for each 
component of the surrogate primary endpoint.  Exposure to 
itraconazole or ketoconazole in the first trimester was also 
assessed.  The individual defects that comprised the primary 
endpoint were as follows: craniosynostosis; cleft palate 
alone; cleft lip, cleft palate, or both; other craniofacial 
defects; middle-ear defects; limb defects; limb-reduction 
defects; polydactyly; syndactyly; diaphragmatic hernia; any 
heart defects; tetralogy of Fallot; pulmonary-artery 
hypoplasia; ventricular septal defects; and hypoplastic left 
heart.  The authors failed to find increased risk of overall 
major birth defect due to FLU exposure during the first 
trimester [crude POR = 1.10 (95% CI, 0.96-1.27)].  Among the 
individual birth defects, oral FLU during the first trimester 
was associated with an increased incidence of tetralogy of 
Fallot [crude POR = 3.21 (95% CI, 1.52-6.81)].  No significant 
association was found with exposure to itraconazole or 
ketoconazole and risk of birth defects [crude POR 
itraconazole = 1.24 (95% CI, 0.81-1.90); crude POR 
ketoconazole = 1.07 (95% CI, 0.26-4.37)].  A subanalysis that 
included terminated pregnancies found a significant 
association between exposure to FLU and hypoplastic left 
heart [adjusted POR = 2.82 (95% CI, 1.23-6.45)] when 
“proportion of terminated pregnancies was assumed to be 
doubled among the exposed pregnancies”.17 
 
Discussion 
The results of the primary literature document that FLU has 
been implicated in causing congenital malformations, 
especially when administered in high doses over a prolonged 
duration of therapy. 
 
A comprehensive literature review of the literature identified 
fourteen citations evaluating or discussing FLU use in 
pregnancy and congenital malformations.  Six citations (four 
case reports, one case series comprised of two cases, and one 
cross-sectional study) associated FLU exposure during 
pregnancy with congenital malformations.  Seven citations 
(three registry based cohort studies, one prospective cohort 
study, one case report, two letters to the editor) found no 
association between FLU exposure and birth defects.  One 
citation (a registry-based cohort study) found no association 
between oral FLU exposure during the first trimester of 
pregnancy and major birth defects as a composite measure, 
but when examining individual birth defects the investigators 
did find an increased incidence of tetralogy of Fallot.  Those 
citations linking FLU exposure with congenital malformations 
implicated its use in the development of craniofacial, skeletal, 
cardiac, and genitourinary malformations, among others. 
 
A number of references11,14,19 noted similarities between the 
malformations associated with FLU teratogenicity and those 
associated with Antley-Bixler syndrome, an autosomal 
recessive disorder of poorly understood etiology.  Antley-
Bixler syndrome has been associated with mutations in 
cytochrome P450 oxidoreductase27,28 and CYP51 (lanosterol-
14 demethylase)29,30 among other mutations.  As reported by 
Lee et al.11, the phenotype characteristics associated with 
Antley-Bixler syndrome include craniofacial malformations 
such as brachycephaly, craniosynostosis, and midfacial 
hypoplasia; skeletal malformations such as radiohumeral 
synostosis, femoral bowing/fractures, thin ribs, 
arachnodactyly, syndactyly; and genitourinary malformations 
such as vaginal atresia and renal abnormalities, in addition to 
other malformation such as hydrocephalus, atrial septal 
defects, preauricular tags, and hemangioma.11   
 
The possible teratogenic effects of FLU appear to be highly 
dependent upon the dose, duration of exposure, and timing 
of exposure relative to conception.  The paucity of significant 
findings among the five cohort studies can most likely be 
attributed to the dose and duration of FLU, since the total 
FLU exposure in these studies rarely exceeded 300 mg.  In 
contrast, the case reports and case series reporting negative 
FLU effects consisted of prolonged exposure (several months 
in duration) to high doses (400-1200 mg/day).  There was 
only one case report of congenital malformations after a 
single 150 mg dose of FLU19, promulgating theories on 
whether other confounding variables could have been 
contributory to the negative outcome. 
 
In conclusion, there appears to be little to no fetal risk 
resulting from a single dose or short duration antifungal 
therapy with FLU; however, prolonged high-dose FLU 
therapy, such as that required for the treatment of 
coccidioidal meningitis, has potential for teratogenic effects 
and the risk of therapy must be weighed against the benefits. 
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Table 1 – Summary of studies related to fluconazole use in pregnancy and congenital malformations 
Reference Design Exposurea Patientsb Outcome 
Fluconazole associated with increased risk 
Lee 199211 Case Report FLU 400 mg/day from 
before conception 
through delivery for 
coccidioidal meningitis 
22 yo black 
secundigravida with 
disseminated 
coccidioidomycosis 
giving caesarean birth 
to a female infant after 
27 weeks 
Multiple congenital malformations leading to 
death post-birth, including 
craniosynostosis, contractures, 
humeral-radial fusion and other 
skeletal anomalies, and cleft palate 
Pursley 199612 Case Report Case 1: 800mg/day 
through 38 weeks for 
coccidioidal meningitis 
 
Case 2: 400mg/day 
through 4 months 
gestation for coccidioidal 
meningiti 
Case 1: 25 yo giving 
caesarean birth to male 
infant after 38 weeks 
 
Case 2: 22 yo 
multiparous female 
whose 2nd gestation 
was described by Lee et 
al.  4th gestation (Case 
2) was full term 
Case 1:  Multiple congenital malformations 
including skeletal defects (especially 
cranial and long bone) and cardiac 
defects (including tetralogy of Fallot, 
patent ductus arteriosus, and patent 
foramen ovale) 
 
Case 2:   Multiple congenital malformations leading 
to death at 3 months, including 
tracheomalacia, cleft palate, 
proptosis, other various skeletal 
malformations, ventricular septal 
defect, pulmonary artery hypoplasia 
Aleck 199613 Case Report Week 0-4: 400mg/day 
Week 5-9: 800mg/day 
Week 22-31: 1200mg/day 
for coccidioidal 
meningitis 
27 yo multiparous 
female giving cesarean 
birth after 31 weeks 
Soft calvarium, widely separated cranial sutures, 
prominent forehead, mild exorbitism, small 
hemangioma on tip of nose, posteriorly angulated 
ears with over folded helices, bilateral 
radiohumeral synostosis, dysplastic hips 
Lopez-Rangel 200514 Case Report FLU 800 mg/day from 
before conception to 
5th month and from 6th 
month to delivery for 
vaginal candidiasis  
30 yo HIV+ Aboriginal 
female on multiple 
medications giving 
vaginal birth to male 
infant after 37 weeks 
Multiple congenital malformations in infant at 9 
months, including: craniosynostosis, 
proptosis and other recognizable 
dysmorphic facial features, contractures, 
skeletal anomalies, and joint synostosis 
 
Sanchez 199819 Letter –  
Case Report 
FLU 150 mg single dose 
near conception for 
vaginal candidiasis 
38 yo primigravida 
giving caesarean birth 
to a male infant after 
39 weeks 
Multiple congenital malformations leading to 
death at 7 days post-birth, including 
occipital encephalocoele, severe hypoplasia 
of cervical vertebrae, and heart defects  
 
Inman 199421 Cross-sectional Group 1: 150mg x 1 
(n=275) 
Group 2: 50 mg course 
(n=3) 
Group 3: 150 mg x ≥2 
(n=11) 
Survey of prescribers 
for patients receiving 
FLU who became 
pregnant 
Group 1: 5 cases of fetal abnormality 
-FLU exposure 12 weeks prior to last 
menstrual period: bilateral hydronephrosis 
-FLU exposure 15 weeks prior to last 
menstrual period: hooded prepuce, minimal 
hypospadias 
- FLU exposure 8 weeks prior to last 
menstrual period: proximal hypospadias, 
bifid scrotum 
-FLU exposure 1 week prior to last menstrual 
period: minor finger webbing, 3 short fingers 
-FLU exposure 26 weeks prior to last 
menstrual period: still born, Edwards 
Syndrome 
Group 2: no fetal abnormalities 
Group 3: no fetal abnormalities 
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Table 1 Cont – Summary of studies related to fluconazole use in pregnancy and congenital malformations 
Reference Design Exposurea Patientsb Outcome 
Fluconazole associated with decreased risk, or no difference between exposures and non-exposures 
Wiesinger 199618 Case Report 400mg/day IV beginning at 
16 weeks gestation for 18 
days, followed by 
400mg/day PO for 34 
days 
Candida sepsis Healthy female infant 
Krcmery 199620 Letter –  
Case Report 
FLU 600 mg/day for 21 
days starting in 14th 
week of pregnancy for 
fungemia 
24 yo female giving birth 
to infant after 41 weeks 
No malformations present at 18 month follow-up exam 
Campomori 199722 Letter –  
Cross-sectional 
Mean exposure 291mg 
(median 300mg, range 
150-1000), with a mean 
duration of 1 ± 0.3 weeks 
16 pregnant females 
who contacted a drug 
information center 
regarding teratogenic 
effects of FLU 
15 healthy, normally developed babies (1 set of stillbirth, 
but not malformed twins) 
Mastriacovo 199623 Prospective Cohort Mean total exposure = 200 
mg 
▪ Study group - FLU in first 
trimester for vaginal 
candidiasis (n=226) 
▪ Control group –  non-
exposure to FLU (n=452) 
Italian women who 
contacted one of three 
Teratology Information 
Services centers from 
January 1992 through 
June 1994. 
Congenital abnormality OR = 1.07 (95% CI, 0.41-2.77). 
 
Induced abortion  OR  = 5.06 (95% CI, 2.28-11.21). 
Jick 199924 Registry-based 
historical cohort 
▪ Study group - Short-
course FLU in first 
trimester (N=234) for 
vaginal candidiasis 
▪ Control group – non-
exposure to azole drug 
(N=1,629) 
British women giving 
birth to live infants 
Malformations present at birth resulting in treatment 
verified in clinical records: 
     - 4 births in study group (1.7%) and 26 births in control 
group (1.6%) 
     - RR = 1.1 (95% CI, 0.4-3.3) 
     - No duplicate malformations in study group 
Sørensen 199925 Registry-based 
historical cohort 
▪ Study group - FLU use in 
first trimester (N=121) for 
vaginal candidiasis 
▪ Control group – non-
exposure to prescription 
drugs (N=13,327) 
Danish women giving 
birth to live or stillborn 
infants 
Malformations registered until study end: 
     - 4 births in study group (3.3%) and 697 births in control 
group (5.2%) 
     - Crude RR = 0.62 (95% CI, 0.23-1.68) 
     - No duplicate malformations in study group 
Nørgaard 200826 
 
 
 
 
 
 
Registry-based 
historical cohort 
▪ Study group - Short-
course FLU in first 
trimester (N=1,079) for 
vaginal candidiasis 
▪ Control group – non-
exposure to FLU 
(N=170,453) 
Danish women giving 
birth to live or stillborn 
infants after 20 weeks 
gestation 
Malformations registered in first year of life: 
     - 44 births in study group (4.1%) and 6,152 births in 
control group (3.6%) 
     - Crude POR = 1.1 (95% CI, 0.8-1.5)   
     - No significant correlations or trends among individual 
abnormalities analyzed 
     - Common abnormalities in study group included 
cardiovascular, musculoskeletal, and craniofacial 
malformations 
 
Table 1 Cont – Summary of studies related to fluconazole use in pregnancy and congenital malformations 
Reference Design Exposurea Patientsb Outcome 
Fluconazole was associated with both negative and positive results 
Mølgaard-Nielsen 
201317 
Registry-based 
historical cohort 
▪ Study group - FLU in first 
trimester (N=7,352) 
▪ Control group –  non-
exposure to FLU 
(N=968,236) 
All live births in 
Denmark (01/01/1996 – 
03/31/2011) 
Malformations registered in first year of life: 
     - 210 in study group (2.86%) and 25,159 in control group 
(2.60%) 
     - Crude POR = 1.10 (95% CI, 0.96-1.27)   
Tetralogy of Fallot  
     - 7 (0.10%) vs 287 (0.03%) 
     -Crude POR = 3.21 (95% CI, 1.52-6.81) 
aShort-course = 1 to 4 days, byo=years old, OR = odds ratio, POR= prevalence odds ratio 
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